{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Antibiotics",
      "Carbapenem-resistant Enterobacteriaceae",
      "Infection",
      "Outcome",
      "Treatment"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "29571291",
  "DateCompleted": {
    "Year": "2018",
    "Month": "09",
    "Day": "24"
  },
  "DateRevised": {
    "Year": "2020",
    "Month": "12",
    "Day": "09"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2018",
        "Month": "03",
        "Day": "23"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "13",
      "10.1186/s12941-018-0267-8"
    ],
    "Journal": {
      "ISSN": "1476-0711",
      "JournalIssue": {
        "Volume": "17",
        "Issue": "1",
        "PubDate": {
          "Year": "2018",
          "Month": "Mar",
          "Day": "23"
        }
      },
      "Title": "Annals of clinical microbiology and antimicrobials",
      "ISOAbbreviation": "Ann Clin Microbiol Antimicrob"
    },
    "ArticleTitle": "Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven\u00a0years retrospective study in three tertiary care hospitals.",
    "Pagination": {
      "StartPage": "13",
      "MedlinePgn": "13"
    },
    "Abstract": {
      "AbstractText": [
        "The increasing incidence of carbapenem-resistant Enterobacteriaceae (CRE), has resulted in a difficult problem in the current clinical anti-infective treatment. We performed a retrospective analysis of prevalence and treatment for CRE infections patients.",
        "This study was conducted in three tertiary care hospitals from January 1, 2010 to December 30, 2016. Baseline data, treatment, and outcomes were collected in patients with ventilator-associated bacterial pneumonia (VABP), bacteremia, complicated urinary tract infection (cUTI)/acute pyelonephritis (AP), hospital-acquired bacterial pneumonia (HABP), superficial wound infection (SWI), biliary tract infection (BTI), deep wound infection (DWI) and sterile body fluids infection (SBFI) due to CRE.",
        "One hundred twenty-four cases of CRE infection were identified: 31 VABP, 22 bacteremia, 18 cUTI/AP, 16 HABP, 16 SWI, 9 BTI, 7 DWI and 5 SBFI. The patient population had significant immunocompromised (33 of 124, 26.6%) and severe sepsis (43 of 124, 34.7%). The most common CRE pathogens were Klebsiella pneumoniae (84 of 124, 67.7%) and Enterobacter cloacae (24 of 124, 19.4%). And the production of IMP-type carbapenemase was the main antibiotic resistance mechanism. The majority of patients to take monotherapy for empiric therapy and dual therapy for direct treatment. Outcomes were universally poor (28-day mortality was 22.6%, 28 of 124) across all sites of infection.",
        "We identified a large number of cases of CRE infection in 7\u00a0years from different parts, most of these pathogens have been confirmed to produce IMP-type carbapenemases. The retrospective analysis of cases of such bacterial infections will help to control future infections of these pathogens. Despite the high mortality rate, we still found that the selection of quinolone antibiotics can be effective in the treatment of CRE producing IMP type enzymes."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong, People's Republic of China."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Laboratory, Liaocheng People's Hospital, Liaocheng, 252000, Shandong, People's Republic of China."
          }
        ],
        "LastName": "Pang",
        "ForeName": "Feng",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Pharmacy, Liaocheng People's Hospital, Liaocheng, 252000, Shandong, People's Republic of China. jiaxiuqin11@163.com."
          }
        ],
        "LastName": "Jia",
        "ForeName": "Xiu-Qin",
        "Initials": "XQ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Laboratory, Liaocheng People's Hospital, Liaocheng, 252000, Shandong, People's Republic of China."
          }
        ],
        "LastName": "Zhao",
        "ForeName": "Qi-Gang",
        "Initials": "QG"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, 250012, Shandong, People's Republic of China."
          }
        ],
        "LastName": "Zhang",
        "ForeName": "Yi",
        "Initials": "Y"
      }
    ],
    "GrantList": [
      {
        "GrantID": "ZR2014HL090",
        "Agency": "Natural Science Foundation of Shandong Province",
        "Country": ""
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Ann Clin Microbiol Antimicrob",
    "NlmUniqueID": "101152152",
    "ISSNLinking": "1476-0711"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Bacterial Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged, 80 and over"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Bacterial Agents"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Bacteremia"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "microbiology"
      ],
      "DescriptorName": "Biliary Tract Diseases"
    },
    {
      "QualifierName": [
        "microbiology"
      ],
      "DescriptorName": "Body Fluids"
    },
    {
      "QualifierName": [
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "Carbapenem-Resistant Enterobacteriaceae"
    },
    {
      "QualifierName": [],
      "DescriptorName": "China"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Cross Infection"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Drug Resistance, Multiple, Bacterial"
    },
    {
      "QualifierName": [
        "pathogenicity"
      ],
      "DescriptorName": "Enterobacter cloacae"
    },
    {
      "QualifierName": [
        "drug effects",
        "isolation & purification",
        "pathogenicity"
      ],
      "DescriptorName": "Enterobacteriaceae"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "microbiology"
      ],
      "DescriptorName": "Enterobacteriaceae Infections"
    },
    {
      "QualifierName": [
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "Escherichia coli"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Hospitalization"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Hospitals"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Intensive Care Units"
    },
    {
      "QualifierName": [
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "Klebsiella oxytoca"
    },
    {
      "QualifierName": [
        "pathogenicity"
      ],
      "DescriptorName": "Klebsiella pneumoniae"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Pneumonia"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "microbiology"
      ],
      "DescriptorName": "Pneumonia, Ventilator-Associated"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prevalence"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Pyelonephritis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Retrospective Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Sepsis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Tertiary Care Centers"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Urinary Tract Infections"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Wound Infection"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Young Adult"
    }
  ]
}